Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00241_DB00458_nanopub.RAGDOqnYVYN_TLub-Tk75bvbQpDKtv9LK4F6gOk8xnFb4#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00241_DB00458 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00241_DB00458 label "DDI between Butalbital and Imipramine - Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as imipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. [drugbank_resource:DB00241_DB00458]" assertion.
- drugbank_resource:DB00241_DB00458 identifier "drugbank_resource:DB00241_DB00458" assertion.
- drugbank_resource:DB00241_DB00458 title "DDI between Butalbital and Imipramine - Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as imipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation." assertion.
- drugbank:DB00458 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00241_DB00458 assertion.
- drugbank:DB00241 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00241_DB00458 assertion.